Research Article

      Abstract    

        

HOME

LUPUS ANTICOAGULANT AND SEVERE PRE-ECLAMPSIA OR ECLAMPSIA: A HOSPITAL-BASED CASE-CONTROL STUDY IN OUAGADOUGOU, BURKINA FASO

SAWADOGO Salam, MINOUNGOU née OUATTARA Aminata, NEBIE Koumpingnin, NIKIEMA née MINOUNGOU Myriam, SANOU Aboubacar, MILLOGO Tieba, KAFANDO Eléonore

 

ABSTRACT: Background: Antiphospholipid antibodies are recognized to be associated to thrombosis and obstetric complications. Preeclampsia is a frequent pregnancy complication in our context. The objective of our study was to determine the prevalence of lupus anticoagulant (LA) and its association with severe pre-eclampsia and eclampsia in Burkina Faso. Methods: We carried out a hospital-based unmatched case-control study including 86 women with severe preeclampsia or eclampsia and 87 controls. LA were diagnosed using Diluted Russel's Viper Venom time screening and confirmation tests. Positive lupus anticoagulant was defined if the screen to confirmation ratio was over 1.2. Results: The prevalence of LA was 22.1% in women with preeclampsia or eclampsia and 3.4% in control (OR = 6.12; 1.45 – 25.84; p = 0.014). The primigravida accounted for68.2% of positive LA and had 2.69 odds of being positive to lupus anticoagulant compared to multigravida (OR = 2.69; [1.04 – 6.97]; p = 0.042). The LA could be suspected to be a part of the aetiologies of obstetrical complications (cases of obstetric antiphospholipid syndrome) in four cases (4.6%) of study-group.  Conclusion: We certainly failed to diagnosis all cases of obstetric antiphospholipid syndrome in our study population, since we screened only LA. It is necessary to implement complementary assays for antiphospholipid antibodies detection in order to improve the exploration of pregnancy complications and thrombotic diseases.

 

KEY WORDS: Lupus anticoagulant – Preeclampsia – Antiphospholipid antibody -Diluted Russel's Viper Venom Time

REFERENCES:

  1. Cervera R. Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome. Curr Rheumatol Rep. 2010;12,1:70-76.

  2. Visseaux B, Masliah-Planchon J, Fischer A-M, Darnige L. Antiphospholipid syndrome diagnosis: an update. Ann Biol Clin (Paris). 2011;69,4:411-418.

  3. Vashisht A, Regan L. Antiphospholipid syndrome in pregnancy – an update. J R Coll Physicians Edinb. 2005; 35:337-339.

  4. 4Cuadrado MJ, Lopez-Pedrera C. Antiphospholipid syndrome. Clin Exp Med. 2003;3,3:129-139.

  5. Branch DW, Gibson M, Silver RM. Recurrent Miscarriage. N Engl J Med. 2010;363,18:1740-747.

  6. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum. 1991;34,10:1231-1235.

  7. Mankee A, Petri M, Magder LS. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. Lupus Sci Med. 2015;2, e000095:5.

  8. Abrahams VM, Chamley LW, Salmon JE. Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation: PATHOGENESIS OF OBSTETRIC APS. Arthritis Rheumatol. 2017;69,9:1710-1721.

  9. Parke AL. Placental Pathology in Antiphospholipid Syndrome. In: Khamashta MA, éditeur. Hughes Syndrome. London: Springer-Verlag;2006;362-374.

  10. 10.Tong M, Viall CA, Chamley LW. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update. 2015;21,1:97-118.

  11. Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. BJOG Int J Obstet Gynaecol. 1972;79,9:794-799.

  12. Predoi C, Grigoriu C, Vladescu R, Mihart A. Placental damages in preeclampsia – from ultrasound images to histopathological findings. J Med Life. 2015; 8:62-65.

  13. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol. 2014;210,1:66. e1-66. e7.

  14. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. The Lancet. 2016;387,10022:999-1011.

  15. American College of Obstetricians and, Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. Int J Gynecol Obstet. 2002;77,1:67-75.

  16.  Kanyala E, Ouédraogo B, Kiemtoré S, Kaboré C, Bonané/Thiéba B. Décès maternels par prééclampsie dans le département de gynécologie et d’obstétrique du CHU Yalgado Ouédraogo. Med Afr Noire. 2019 ;6601 :54-62.

  17. N'dhatzENC, Packo D-L-VS-CS, Nanho DC, KaramaI, BoidyK, Diakité M,Mbelesso P, Koffi KG. Le Syndrome des anticorps anti phospholipides : une étiologie des fausses couches laquelle on ne pense pas souvent en Afrique noire. Eur Sci J. 2019;15,30:172-182.

  18. Bouter AR, Duvekot JJ. Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia. Pregnancy Hypertens. 2020 ;19 :206-211.

  19. Organisation Mondiale de la Santé. Recommandations pour la pratique clinique des soins obstétricaux et néonataux d’urgence en Afrique : guide du prestataire. Brazaville: OMS/AFRO; 2018. Report No.: Licence : CC BY-NC-SA 3.0 IGO.

  20. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. Obstet Gynecol. 2019;133: e1-e25.

  21. Marchetti T, Cohen M, de Moerloose P. Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications. Clin Dev Immunol. 2013;2013, Article ID 159124:1-9.

  22. An G-D, Lim H-H, Han J-Y. Laboratory Diagnosis of Antiphospholipid Syndrome. Clin Exp Thromb Hemost. 2017;3,1:2-7.

  23. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol. 2009;83,1:1-16.

  24. Ortel TL. Antiphospholipid syndrome: Laboratory testing and diagnostic strategies. Am J Hematol. 2012;87, S1:S75-81.

  25. Sysmex Educational Enhancement & Development. Lupus Anticoagulant testing in the coagulation laboratory. SEED-Afr Newsl. 2012; 2:1-7.

  26. Moore G. Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants. Semin Thromb Hemost. 2014;40,02:163-171.

  27. Depreter B, Devreese KMJ. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice. Clin Chem Lab Med CCLM. 2017;55,1:91-101.

  28. Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J. Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines: Lupus anticoagulant: performance of the tests. J Thromb Haemost. 2011;9,9:1776-1783.

  29. Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F, Tona F, Pengo V. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost. 2006;96,09:337-341.

  30. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93,06:1147-1152.

  31. Awodu O, Shokunbi W, Ejele O, Ejele O, Shokunbi W. Lupus anticoagulant in Nigerian women with preeclampsia. West Afr J Med. 2004;22,3:240-242.

  32. Nwogoh B, Awodu OA, Aziken ME, Nwannadi AI. Antiphospholipid Antibodies in Women with Preeclampsia Seen at the University of Benin Teaching Hospital, Benin City, Nigeria. Int J Health Sci Res. 2014;4,2:140-148.

  33. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14,4:675-684.

  34. Wilson WA, Cucurull E. Ethnic and Geographic Variation in Antiphospholipid Syndrome. In : Khamashta MA, éditeur. Hughes Syndrome [Internet]. London : Springer-Verlag; 2006 [cité 18 avr 2021]. p. 258-63.

  35. Uthman I. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis. 2005;64,12:1671-1676.

  36. Ibrahim IN, Mamman AI, Adaji SE, Hassan A, Babadoko AA. Prevalence of lupus anticoagulant in women with spontaneous abortion in Zaria. Niger J Clin Pract. 2017; 20:1145-1149.

  37. Dreyfus M. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol. 2001;97,1:29-34.

  38. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb Res. 2011;128,1:77-85.

  39. Gibbins KJ, Tebo AE, Nielsen SK, Branch DW. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. Lupus. 2018;27,12:1903-1910.

  40. Galli M. Interpretation and Recommended Testing for Antiphospholipid Antibodies. Semin Thromb Hemost. 2012;38,04:348-352.

  41. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7,10:1737-1740.

  42. Perches PG, Domingues DP, Gomes AL, Ribeiro AM, Pereira FMT, Rassi IE. Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome. Bras J Rheumatol. 2009;49,3:236-245.

  43. Moore G. Current Controversies in Lupus Anticoagulant Detection. Antibodies. 2016;5,22:15.

  44. Laffan M, Manning R. Investigation of Haemostasis. In: Dacie and Lewis practical haematology. 11th éd. Edinburgh: Elsevier Churchill Livingstone; 2012.

 To cite this article:

Salam S, Aminata MO, NEBIE Koumpingnin N, NIKIEMA née MINOUNGOU Myriam NM, Aboubacar S, Tieba M, Eléonore K. Lupus anticoagulant and severe pre-eclampsia or eclampsia: a hospital-based case-control study in ouagadougou, burkina faso. Int. J. Med. Lab. Res. 2021; 6,3:1-10.http://doi.org/10.35503/IJMLR.2021.6301